USPTO Examiner JACKSON TONGUE LAKIA J - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18768920BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOFJuly 2024February 2025Allow710YesNo
18744293METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIESJune 2024December 2024Allow610YesNo
18620483Method and System to Modify an Individual�s Gut-Brain Axis to Provide Neurocognitive ProtectionMarch 2024February 2025Allow1010NoNo
18615672Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone DiseaseMarch 2024March 2025Allow1120YesNo
18559543CANCER THERAPY WITH LIVE ATTENUATED BACTERIANovember 2023October 2024Allow1110YesNo
18489869METHODS FOR IMPROVING SKIN CONDITION, HAIR HEALTH, ANTI-INFLAMMATION ACTIVITY, CARDIOVASCULAR HEALTH, ANTI-OXIDATION ACTIVITY, ANTI-AGING ACTIVITY, AND/OR RELIEVING BODY FATIGUE BY USING YEAST POWDER RICH IN NICOTINAMIDE MONONUCLEOTIDEOctober 2023June 2025Allow2010NoNo
18243566METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIESSeptember 2023June 2024Allow1020YesNo
18455329BIFIDOBACTERIUM LONGUM NCIMB 41676August 2023June 2025Allow2110NoNo
18453684VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUISAugust 2023July 2024Allow1110NoNo
18232433Probiotic Method and Composition for Maintaining a Healthy Vaginal MicrobiomeAugust 2023January 2024Allow610YesNo
18336974MEDICAL CELL CMU-pb-7 AND APPLICATION THEREOF IN PREPARATION OF ANTIOXIDANT DRUGSJune 2023August 2024Abandon1420NoNo
18295874COMPOSITIONS COMPRISING BACTERIAL STRAINSApril 2023May 2025Abandon2510NoNo
18149950PSEUDOMONAS MONTEILII STRAIN AND APPLICATION THEREOF IN THE DEGRADATION OF PETROLEUM HYDROCARBONS IN SALINE-ALKALI ENVIRONMENTJanuary 2023February 2024Allow1311NoNo
18057333MONOCLONAL ANTIBODY AGAINST D-DIMER AND DIAGNOSIS AGENT FOR DETECTING D-DIMER, CROSSLINKED FIBRIN AND ITS DERIVATIVES CONTAINING D-DIMER BY USING THE ANTIBODYNovember 2022June 2025Allow3010NoNo
17986286Methods Of Vaccine AdministrationNovember 2022January 2025Allow2610YesNo
18049704METHODS TO SPATIALLY PROFILE PROTEASE ACTIVITY IN TISSUE AND SECTIONSOctober 2022February 2025Allow2710NoNo
18047586Virulence Attenuated Bacteria Based Protein DeliveryOctober 2022January 2025Allow2710YesNo
17934166ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOFSeptember 2022November 2024Allow2510NoNo
17932685PNEUMOCOCCAL FUSION PROTEIN VACCINESSeptember 2022June 2024Allow2100YesNo
17931876SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATIONSeptember 2022January 2025Allow2820NoNo
17819199ANTI-O2 ANTIBODIES AND USES THEREOFAugust 2022January 2025Allow2910NoNo
17869055IMMUNOGENIC COMPOSITION COMPRISING STAPHYLOCOCCAL ANTIGENSJuly 2022December 2024Abandon2910NoNo
17862282TREATMENT OF DIABETES AND CHRONIC PANCREATITIS USING BOTULINUM TOXINJuly 2022November 2023Allow1620NoNo
17789149ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING PROBIOTICS AND ANTIBIOTICS, AND METHOD USING SAMEJune 2022April 2025Abandon3310NoNo
17784690CRYPTOSPORIDIOSIS VACCINEJune 2022July 2025Allow3711NoNo
17750083TREATING AND PREVENTING MICROBIAL INFECTIONSMay 2022June 2025Allow3611YesNo
17748875TREATING AND PREVENTING MICROBIAL INFECTIONSMay 2022June 2023Allow1320NoNo
17747689ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOFMay 2022November 2024Allow3010NoNo
17728793TREATING AND PREVENTING MICROBIAL INFECTIONSApril 2022February 2023Allow910NoNo
17660558LIVE ATTENUATED ORAL VACCINE AGAINST SHIGELLOSIS AND TYPHOID FEVERApril 2022May 2025Allow3610NoNo
17709277BACILLUS SUBTILIS STRAINS IMPROVING ANIMAL PERFORMANCE PARAMETERSMarch 2022March 2025Allow3520YesNo
17656903COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERSMarch 2022January 2025Allow3411YesNo
17656897COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERSMarch 2022August 2024Allow2810YesNo
17655687PROPHYLACTIC AND/OR THERAPEUTIC AGENT OF INFECTIOUS DISEASES OR INFLAMMATORY DISEASESMarch 2022December 2024Allow3310NoNo
17695569ANTIBODY MOLECULES AND USES THEREOFMarch 2022October 2024Allow3100YesNo
17670818METHODS OF DETECTION OF COMPOUND, ANTIBODY OR PROTEIN USING RECOMBINANT ENDOSPORES OR BACTERIA AS SENSING ELEMENTFebruary 2022April 2025Allow3811NoNo
17665130PLATFORM FOR GENERATING SAFE CELL THERAPEUTICSFebruary 2022March 2023Allow1320NoNo
17589484UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTIONJanuary 2022February 2025Abandon3601NoNo
17569377BINDING MOIETIES FOR BIOFILM REMEDIATIONJanuary 2022July 2024Allow3010NoNo
17645344COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASEDecember 2021January 2025Abandon3701NoNo
17554531PLATFORM FOR GENERATING SAFE CELL THERAPEUTICSDecember 2021November 2024Allow3510NoNo
17547211METHODS OF TREATMENT FOR CERVICAL DYSTONIADecember 2021November 2024Allow3510NoNo
17545486ANTI-GALACTOFURANOSE ANTIBODIES FOR DETECTING AND TREATING ASPERGILLOSISDecember 2021December 2024Allow3611YesNo
17505048ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONSOctober 2021December 2022Abandon1311YesNo
17502320METHOD FOR LATERAL FLOW IMMUNOASSAYOctober 2021March 2024Allow2910NoNo
17503032METHODS OF TREATMENT OF INFECTIONS USING BACTERIAOctober 2021April 2025Allow4211NoNo
17498136ANTI-PHYTOPATHOGENIC COMPOSITIONSOctober 2021June 2024Abandon3210NoNo
17497295MULTIPLE VIRAL ANTIGEN COVID VACCINE AND THERAPEUTICOctober 2021June 2022Allow910NoNo
17490735Anti-CD47 monoclonal antibody and use thereofSeptember 2021April 2025Allow4311YesNo
17411067Preparation method of yeast powder rich in nicotinamide mononucleotide, yeast powder, and methods for improving skin condition, hair health, antiinflammation, cardiovascular health, antioxidation, antiaging and/or relieving body fatigueAugust 2021August 2023Allow2400NoNo
17402220CHEMICAL SENSOR DEVICE AND CHEMICAL SENSOR MODULEAugust 2021May 2024Allow3310YesNo
17397474ANTI-O1 ANTIBODIES AND USES THEREOFAugust 2021February 2024Allow3011YesNo
17391103CD40 LIGAND FUSION PROTEIN VACCINEAugust 2021November 2023Abandon2811NoNo
17389982STAPHYLOCOCCUS PSEUDINTERMEDIUS VIRULENCE FACTOR COMPOSITIONSJuly 2021May 2024Allow3310YesNo
17382426COMPOSITIONS COMPRISING BACTERIAL STRAINSJuly 2021April 2024Abandon3210NoNo
17371449Production of Soluble Recombinant Proteins without N-Terminal Methionine in E-ColiJuly 2021August 2024Allow3710NoNo
17368494COMPOSITION AND METHODS FOR MICROBIOTA THERAPYJuly 2021December 2022Allow1731YesNo
17305236VACCINE FOR PROTECTION AGAINST ETEC-INDUCED DIARRHEA COMPRISING DMLTJuly 2021October 2023Allow2811NoNo
17346452BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USEJune 2021February 2024Allow3210NoNo
17343901COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL OR MENTAL DISORDERS COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEIJune 2021January 2023Allow1921NoNo
17297923SYSTEM AND METHOD FOR INTEGRATION OF BIOLOGICAL CHIPSMay 2021June 2024Allow3710NoNo
17328657PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATESMay 2021January 2025Allow4410NoNo
17291010NUCLEIC ACID SEQUENCE MEASUREMENT DEVICEMay 2021October 2024Allow4210NoNo
17287238NEW PROBIOTICS USEFUL FOR ERADICATING HELICOBACTER PYLORI INFECTIONApril 2021February 2024Allow3410YesNo
17226148COMPOSITIONS COMPRISING BACTERIAL STRAINSApril 2021April 2023Abandon2410NoNo
17223710Microbiome-based informed method to formulate live biotherapeuticsApril 2021March 2022Allow1110NoNo
17223754Microbiome-based informed method to formulate live biotherapeuticsApril 2021May 2022Allow1420NoNo
17280708COMPOSITIONS AND METHODS FOR TREATING EPILEPSY AND RELATED DISORDERSMarch 2021October 2023Allow3120NoNo
17210957METHODS FOR TESTING SKIN SAMPLESMarch 2021October 2023Allow3120NoNo
17208797EDIBLE VACCINATION AGAINST MICROBIAL PATHOGENSMarch 2021March 2024Allow3610YesNo
17277138IMMUNOLOGICAL ADJUVANT AND VACCINE COMPOSITION INCLUDING STING AGONISTMarch 2021January 2025Abandon4620NoNo
17275401HOST BACTERIUM SPECIFIC NANOPARTICLEMarch 2021December 2023Allow3310YesNo
17199106TREATING AND PREVENTING MICROBIAL INFECTIONSMarch 2021July 2022Allow1620NoNo
17184242COMPOSITIONS COMPRISING BACTERIAL STRAINSFebruary 2021May 2024Abandon3910NoNo
17175925NANOVESICLE DERIVED FROM PROTEUS GENUS BACTERIA, AND USE THEREOFFebruary 2021September 2023Allow3110NoNo
17264821ORALLY ADMINISTERED SUPPLEMENTS AND METHODS OF REDUCING ABSORPTION OF CALORIES AND MODIFYING THE NUTRITIONAL VALUES OF CONSUMED NUTRIENTSJanuary 2021December 2023Abandon3401NoNo
17159595PLATFORM FOR GENERATING SAFE CELL THERAPEUTICSJanuary 2021June 2021Allow510NoNo
17156477MYCOPLASMA VACCINES AND USES THEREOFJanuary 2021November 2024Allow4621YesYes
17261532FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATIONJanuary 2021February 2024Allow3720YesNo
17148592METHOD FOR TESTING ECOTOXICITY OF DISINFECTION BY-PRODUCTSJanuary 2021September 2023Allow3200YesNo
17259889TREATMENT METHODS AND COMPOSITIONSJanuary 2021January 2024Allow3620YesNo
17140832METHOD OF ATTACKING TARGET CELLSJanuary 2021August 2024Abandon4410NoNo
17256428METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETESDecember 2020October 2023Allow3410NoNo
17132624SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATIONDecember 2020May 2022Allow1720NoNo
17121621MSP NANOPORES AND RELATED METHODSDecember 2020December 2022Allow2430YesNo
17251973ESCHERICHIA COLI 0157:H7 PROTEINS AND USES THEREOFDecember 2020August 2022Abandon2011NoNo
17104456METHOD FOR INCREASING ETEC CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND PRODUCTS OBTAINABLE THEREOFNovember 2020July 2023Allow3210NoNo
17058978DYNAMIC CLAMPS AND METHODS OF USE THEREOFNovember 2020November 2024Allow4811YesNo
17058277Colloidal Particles Functionalized Homogeneously by BiomoleculesNovember 2020December 2024Allow4811YesNo
17098021ANTIBODIES FOR PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTIONNovember 2020October 2022Allow2311NoNo
17096890METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIESNovember 2020June 2023Allow3201NoNo
17089172IMMUNOSTIMULATORY COMPOSITIONSNovember 2020September 2023Allow3410NoNo
17051993TUBERCULOSIS VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOFOctober 2020June 2022Allow2010NoNo
16949415ANTI-PD-L1 ANTIBODY FOR DETECTING PD-L1October 2020February 2023Allow2821YesNo
17082008NANO-VESICLES DERIVED FROM GENUS MORGANELLA BACTERIA AND USE THEREOFOctober 2020October 2023Allow3511NoNo
17073879ANTI-PSEUDOMONAS PSL BINDING MOLECULES AND USES THEREOFOctober 2020July 2023Abandon3301NoNo
17068173IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARISOctober 2020February 2023Allow2810YesNo
17061687Bioconjugates Made From Recombinant N-Glycosylated Proteins From Procaryotic CellsOctober 2020September 2023Allow3611YesNo
17039255COMPOSITIONS COMPRISING BACTERIAL STRAINSSeptember 2020June 2023Abandon3310NoNo
17037455ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOFSeptember 2020June 2022Allow2051NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JACKSON-TONGUE, LAKIA J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
6
(50.0%)
Examiner Reversed
6
(50.0%)
Reversal Percentile
69.3%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
88
Allowed After Appeal Filing
17
(19.3%)
Not Allowed After Appeal Filing
71
(80.7%)
Filing Benefit Percentile
21.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner JACKSON-TONGUE, LAKIA J - Prosecution Strategy Guide

Executive Summary

Examiner JACKSON-TONGUE, LAKIA J works in Art Unit 1645 and has examined 735 patent applications in our dataset. With an allowance rate of 66.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner JACKSON-TONGUE, LAKIA J's allowance rate of 66.5% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JACKSON-TONGUE, LAKIA J receive 2.12 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JACKSON-TONGUE, LAKIA J is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +18.7% benefit to allowance rate for applications examined by JACKSON-TONGUE, LAKIA J. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.5% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.0% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.1% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.